

February 24, 2023

Sodium Acetate Injection, USP 4 mEq/mL SD Vial 50 mL
Availability Notice

Dear Valued Customer,

Fresenius Kabi Canada is pleased to advise that our **Sodium Acetate Injection, USP 4 mEq/mL SD Vial 50 mL** will be available at all distribution centres by **March 10, 2023**. Once available, this product will be placed on allocation. Contract customers will be allocated **100% of historical monthly demand of the 50 mL plus 100% of historical monthly demand of the 100 mL at a 2:1 ratio** (2 vials of 50 mL = 1 vial of 100 mL).

Please refer to our recent Healthcare Professional Communication “**Important Safety Information Sodium Acetate Injection, USP – Potential for the Development of Particulate Matter**” dated February 23, 2023, for important guidance relating to use of this product (https://www.fresenius-kabi.com/en-ca/documents/HPRC-Sodium-Acetate-Injection-Lot-6126849_ENG_23FEB2023.pdf).

Allocations are expected to be in place until May 31, 2023; thereafter, all inventory is anticipated to be depleted. Long term supply status is currently unknown; however, we assure you that we are working diligently with our plants for a resolution.

DIN	Fresenius Kabi Product Code	MDP Product Code	McKesson Product Code	Product Description	Availability Date
02139529	C3250	922833	594226	Sodium Acetate Injection, USP 4 mEq/mL SD Vial 50 mL	At all distribution centres by: Mar. 10, 2023

Thank you for your patience and understanding during our supply interruption and please do not hesitate to contact your sales representative with any questions or concerns.

Sincerely,

George Shamsoun
Director of Marketing, Generics and Nutrition
george.shamsoun@fresenius-kabi.com